Abstract Details

Title The Impact of a Portable Artificial Vision Device (OrCam Read) on Vision-Related Quality-of-Life in Patients with Primary Brain Tumors and Low Vision

Topic Neuro-ophthalmology/Neuro-otology

Presentation(s) P18 - Poster Session 18 (5:30 PM-6:30 PM)

Poster/Presentation
Number 2-001

Background

Quality of life is an important area of clinical neuro-ophthalmology that is increasingly relevant as survivorship increases and as patients experience potential morbidities associated with new therapies. OrCam Read is a handheld artificial vision device with a smart camera that reads texts from both printed surfaces and digital screens.

Objective This study aims to evaluate the impact of the OrCam Read device on vision-related quality-of-life (QoL) in patients with primary brain tumors and low vision.

Design/Methods

A single center prospective observational study is being conducted since June 1, 2021, with a goal recruitment of 15 participants with primary brain tumors who sustain low vision because of their tumors and treatments. OrCam Read device training is provided to the patients upon enrollment. The study duration is 1 month with weekly telephone calls and end-of-study satisfaction surveys. The endpoints are to determine 1) the feasibility of integrating the OrCam Read device into the patient’s lifestyle, 2) changes in daily function tasks and QoL using the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) and the 10-item neuro-ophthalmic supplement before and after the introduction of the device, and 3) patient satisfaction.

Results Our first patient has an astrocytoma involving the right temporo-parietal lobe resulting in a left homonymous hemianopia. His best corrected visual acuity is 20/20 of each eye. After 1 month using the OrCam Read, his NEI-VFQ-25 improved from 75 to 64 (better daily activities). In the satisfaction survey, he expressed being highly likely to use this device every day and would recommend it to another visually impaired person.

Conclusions OrCam Read device is likely feasible and helpful for daily actives and improve QoL for brain tumor patients with visual field defect from our first patient’s experience. Further larger study is needed to understand the benefits of this device among primary brain tumor patients with visual impairment.

Authors/Disclosures
Tanvi Chokshi PRESENTER	Miss Chokshi has nothing to disclose.
Yin A. Liu, MD (UC Davis)	Dr. Liu has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Myrobalan. Dr. Liu has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Argenx.